Results 101 to 110 of about 1,936 (153)

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates

open access: yesBMC Infectious Diseases
Background Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities.
Dalia Salem   +5 more
doaj   +1 more source

Activity of ceftolozane/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART – Brazil), 2018‒2021

open access: yesBrazilian Journal of Infectious Diseases
Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the in vitro activity of ceftolozane/tazobactam and its comparators ...
Amanda Azevedo Bittencourt   +5 more
doaj   +1 more source

Clinical characteristics, microbiology data and outcome of patients treated with ceftolozane/tazobactam or ceftazidime/avibactam during the study period.

open access: yes, 2018
Clinical characteristics, microbiology data and outcome of patients treated with ceftolozane/tazobactam or ceftazidime/avibactam during the study period.
Juri Katchanov (5095268)   +8 more
core   +1 more source

In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam

open access: yes, 2018
We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012.
Peeters, Charlotte   +8 more
core   +1 more source

Comparison of ceftolozane–tazobactam and ceftazidime–avibactam for the treatment of infections caused by drug-resistant Pseudomonas aeruginosa: an updated systematic review and meta-analysis based on adjusted data from observational studies

open access: yesInternational Journal of Infectious Diseases
Background: Clinical guidelines recommend two novel β-lactam/β-lactamase inhibitor combinations—ceftolozane–tazobactam and ceftazidime–avibactam—as first-line therapies for drug-resistant Pseudomonas aeruginosa infections.
Pengfei Li   +3 more
doaj   +1 more source

Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

open access: yesBMC Health Services Research
Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens.
Risako Takaya   +3 more
doaj   +1 more source

Stability of Two Reserve Antibiotics in Elastomeric Pumps: Ceftazidime-Avibactam and Ceftolozane-Tazobactam

open access: yes
Background/Objectives: Parenteral antibiotic therapy is indispensable in the treatment of several infections. The parenteral administration often leads to the need for prolonged hospitalization.
Katharina M. Rentsch   +8 more
core   +1 more source

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa

open access: yes
Methods: The study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016-22) who received ceftolozane/tazobactam or ceftazidime/avibactam within 3 days of index culture for ≥2 days.
Obi, Engels N.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy